Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) Q1 2023 Earnings Conference Call May 11, 2023 8:30 AM ET
Company Participants
Patrick McEnany - Chairman, Chief Executive Officer
Alicia Grande - Vice President, Chief Financial Officer
Jeff Del Carmen - Chief Commercial Officer
Steven Miller - Chief Operating Officer, Chief Scientific Officer
Conference Call Participants
Les Sulewski - Truist Securities
Joe Catanzaro - Piper Sandler
Pete Stavropoulos - Cantor Fitzgerald
Operator
Greetings and welcome to the Catalyst Pharmaceuticals first quarter 2023 financial results conference call.
At this time, all participants are in a listen-only mode. A brief question and answer session will follow the formal presentation. If anyone should require Operator assistance during the conference, please press star, zero on your telephone keypad. As a reminder, this conference is being recorded.
It is now my pleasure to introduce your host, Ali Grande, Chief Financial Officer. Thank you Ali, you may begin.
Alicia Grande
Good morning everyone. Thank you for joining our conference call to discuss Catalyst’s first quarter 2023 financial results and corporate highlights. Leading the call today is Patrick McEnany, Chairman and Chief Executive Officer. We are also joined by Dr. Steven Miller, our Chief Operating Officer and Chief Scientific Officer, and Jeffrey Del Carmen, our Chief Commercial Officer. Further, for the Q&A session, we will have Dr. Gary Ingenito, our Chief Medical and Regulatory Officer.
Before we begin, I would like to remind you that in our remarks this morning and in the Q&A session, we will make statements about expected future results which may be forward-looking statements for purposes of federal securities laws. These statements relate to our current expectations, estimates and projections and are not guarantees of future performance. They involve risks, uncertainties and assumptions that are difficult to predict and may prove not to be accurate. Actual results may vary from the expectations contained in our forward-looking statements.
The forward-looking statements should be considered only in conjunction with the detailed information contained in our SEC filings, including the risk factors described in our 2022 annual report on Form 10-K.
At this time, I’ll turn the call over to Pat.
Patrick McEnany
Thanks Ali, and welcome everyone to our first quarter 2023 results conference call.
We started 2023 strong as we made meaningful progress across all our functional areas. I’m very pleased to report on our record-breaking first quarter 2023 financial performance as shared in yesterday’s press release, and I will now highlight several key points.